Provided by Tiger Fintech (Singapore) Pte. Ltd.

XILIO THERAPEUTICS, INC.

0.6783
+0.01241.86%
Post-market: 0.68500.0067+0.99%19:49 EDT
Volume:645.41K
Turnover:426.04K
Market Cap:35.12M
PE:-0.81
High:0.6799
Open:0.6667
Low:0.6400
Close:0.6659
Loading ...

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

THOMSON REUTERS
·
8 hours ago

Xilio Therapeutics Announces New Stock Option Grants for Employees Under 2022 Inducement Plan

Reuters
·
04 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Natgas companies, UnitedHealth, Cactus

Reuters
·
03 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Lyra Therapeutics, Church & Dwight, Applied Digital

Reuters
·
02 Jun

Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings

Benzinga
·
02 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Xilio Therapeutics, Red Rock Resorts, Kymera

Reuters
·
02 Jun

Xilio Therapeutics announces pricing of $50M public offering

TIPRANKS
·
02 Jun

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

THOMSON REUTERS
·
02 Jun

BRIEF-Xilio Therapeutics Announces Proposed Public Offering

Reuters
·
02 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Blueprint Medicines, Boeing

Reuters
·
02 Jun

BUZZ-Xilio Therapeutics drops on equity raise plans

Reuters
·
02 Jun

Xilio Therapeutics Announces Proposed Public Offering

THOMSON REUTERS
·
02 Jun

Xilio Therapeutics announces updated Phase 2 data for vilastobart

TIPRANKS
·
02 Jun

BRIEF-Xilio Therapeutics Announces Updated Phase 2 Data For Vilastobart, A Tumor-Activated Anti-Ctla-4, In Combination With Atezolizumab In Patients With Metastatic Microsatellite Stable Colorectal Cancer

Reuters
·
31 May

Xilio Therapeutics Inc - Vilastobart and Atezolizumab Show Well-Tolerated Safety Profile

THOMSON REUTERS
·
31 May

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-Ctla-4, in Combination With Atezolizumab in Patients With Metastatic Microsatellite Stable Colorectal Cancer

THOMSON REUTERS
·
31 May

Xilio Therapeutics Inc - 26% Response Rate in Metastatic Mss Crc Without Liver Metastases

THOMSON REUTERS
·
31 May

Xilio Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Xilio Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
09 May

Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Galmed Pharmaceuticals (GLMD) and Xilio Therapeutics (XLO)

TIPRANKS
·
09 May